CompletedPhase 1NCT02452372
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
Studying Disorder of porphyrin and heme metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- Amy Simon, MDAlnylam Pharmaceuticals
- Intervention
- givosiran (ALN-AS1)(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2015 – 2017
Study locations (6)
- Clinical Trial Site, Birmingham, Alabama, United States
- Clinical Trial Site, San Francisco, California, United States
- Clinical Trial Site, New York, New York, United States
- Clinical Trial Site, Galveston, Texas, United States
- Clinical Trial Site, Stockholm, Sweden
- Clinical Trial Site, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02452372 on ClinicalTrials.govOther trials for Disorder of porphyrin and heme metabolism
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06910358Study of Bitopertin in Participants With EPP or XLP (APOLLO)Disc Medicine, Inc
- ENROLLING BY INVITATIONPHASE2NCT06971900GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic ProtoporphyriaPortal Therapeutics, Inc.
- ACTIVE NOT RECRUITINGNCT02935400Acute Porphyria Biomarkers for Disease ActivityThe University of Texas Medical Branch, Galveston
- ACTIVE NOT RECRUITINGNCT01617642Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)Nordlandssykehuset HF
See all trials for Disorder of porphyrin and heme metabolism →